UNSPSC 51262700: Adrenergic blocking agent imidazolines

This classification denotes adrenergic blocking agents made from compounds based on reduced imidazoles containing a single double bond.

UNSPSC 51262700 Adrenergic blocking agent imidazolines is a Class code that covers pharmaceutical products, though recent state and local opportunities tagged under it diverge significantly from the nominal scope. Seminole County, Florida has solicited naloxone and safe drug deactivation systems through an IFB, while the Texas Health and Human Services Commission issued an RFI exploring direct-to-manufacturer prescription fulfillment models. The actual purchasing activity reflects broader pharmaceutical procurement and harm-reduction supply sourcing rather than a narrow pharmaceutical agent class. Issuing bodies include county health departments and state health agencies managing pharmacy benefits and community health initiatives. The work spans product procurement for emergency medical response (naloxone distribution), drug disposal infrastructure, and strategic program design around pharmacy benefit delivery and manufacturer relationships.

Recent activity is concentrated in Florida and Texas. Seminole County's IFB (IFB60459723LAS, posted June 30, 2026, due July 26, 2026) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, under a two-year initial term with one-year renewal option and fixed-fee pricing. The Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026, response deadline April 3, 2026) is preliminary market intelligence gathering on direct-to-manufacturer pharmacy benefit models, designed to inform future RFP development rather than immediate contracting. The code shows narrow recent activity; the mismatch between the nominal pharmaceutical agent classification and the actual solicitations—which center on public health supplies, harm reduction, and pharmacy program architecture rather than adrenergic agents—suggests this code may not be the primary vehicle for pharmaceutical procurement in state and local markets.